Press Releases

November 12, 2019
Gossamer Bio Announces Third Quarter 2019 Financial Results
– Clinical programs on track for multiple topline data releases in 2020 – – Entered clinical trial collaboration with Merck to evaluate KEYTRUDA ® (pembrolizumab) in combination with GB1275 in advanced solid tumors – – Company to host conference call today at 4:30 p.m.
Additional Formats
November 12, 2019
Gossamer Bio Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA® (Pembrolizumab) in Selected Advanced Solid Tumors
– Phase 1/2 trial ongoing with multiple patients dosed in GB1275 monotherapy dose escalation – – GB1275 granted Orphan Drug Designation for the treatment of pancreatic cancer by the U.S. Food and Drug Administration – – Preclinical data for GB1275 featured as cover article in July 3 rd edition of
Additional Formats
August 8, 2019
Gossamer Bio Announces Second Quarter 2019 Financial Results
– Immuno-oncology candidate, GB1275, advances to clinic for selected solid tumor types – – Five active clinical trials across four clinical programs, with data readouts for all four programs expected in 2020 – – Company to host conference call today at 4:30 p.m.
Additional Formats
Displaying 1 - 10 of 21